

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Burton et al.

Art Unit : 1648

Serial No.: 10/079,802

Examiner: Donna Wortman

Filed

: February 19, 2002

Title

LIGAND CAPTURE-DIRECTED SELECTION OF ANTIBODY

Commissioner for Patents Washington, D.C. 20231

TERMINAL DISCLAIMER UNDER 37 CFR §§3.73(b) AND 1.321(b)

Pursuant to 37 CFR §3.73(b), THE SCRIPPS RESEARCH INSTITUTE, certifies that it is the assignee of the entire right, title, and interest in the above application by virtue of an assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 7330, Frame 0617 on January 23, 1995. The Scripps Research Institute also certifies that it is the assignee of U.S. Patent No. A copy of the assignment is attached for your reference.

The undersigned has reviewed all the documents in the chain of title of the aboveidentified application and to the best of undersigned's knowledge and belief, title is in The Scripps Research Institute.

The undersigned is empowered to act on behalf of the assignee.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, the assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above identified application subsequent to the expiration date of U.S. Patent No. 6,156,313, whereby the patent granted on this application and U.S. Patent No. 6,156,313 will expire on the same day, provided that any patent granted on the above identified application shall be enforceable only for and during such period that it is commonly owned with U.S. Patent No. 6,156,313.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

04/22/2003 BSAYASI1 00000074 10079802

02 FC:1814

110.00 OP

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Depoy

Typed or Printed Name of Person Signing

Attorney's Docket No.: 07300-025002 / TSRI 414.0 Con.1/SCR 1994P

Applicant: Burton et al. Serial No.: 10/079,802 Filed : February 19, 2002

Page : 2 of 2

The assignee identified above does not disclaim any terminal part of any patent granted on the above identified application prior to the expiration date of the full statutory term of U.S. Patent No. 6,156,313 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above. Assignee herein does not disclaim or otherwise affect any part of U.S. Patent No. 6,156,313.

This disclaimer runs with any patent granted on the above application and is binding upon the grantee, its successors or assigns.

Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 07300-025002.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

•

Michael Reed, Ph.D. Reg. No. 45,647

4350 La Jolla Village Drive, Suite 500

San Diego, California 92122 Telephone: (858) 678-5070

Fish & Richardson P.C.

Facsimile: (858) 678-5099

10263590.doc